Latest News and Press Releases
Want to stay updated on the latest news?
-
VARȘOVIA, Polonia, May 07, 2025 (GLOBE NEWSWIRE) -- Pe măsură ce președinția poloneză a Consiliului UE intră în ultima sa etapă, politica privind sănătatea rămâne în topul agendei strategice a...
-
VARSÓ, Lengyelország, May 07, 2025 (GLOBE NEWSWIRE) -- Az Európai Tanács jelenlegi elnökségét ellátó Lengyelország elnöki periódusa a végéhez közeleg, de az egészségpolitika Európa...
-
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe’s strategic agenda. At the European...
-
PARIS and TARRYTOWN, N.Y., June 9, 2015 (GLOBE NEWSWIRE) -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the...
-
PARIS, March 19, 2015 (GLOBE NEWSWIRE) -- Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk...
-
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine - Robust and consistent LDL-C lowering...
-
PARIS and VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide...
-
- 88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world's first phase III efficacy study published in The Lancet - - Two thirds reduction in hospitalization observed...
-
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b...
-
Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) - Meta-analysis of three late-stage trials in people with type 2 diabetes shows...